Trial · NCT00092677
Results by group38
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 38
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants That Experienced One or More Components of the Composite Clinical Endpoint of MCE (Major Cardiovascular Events) | EZ/Simva 10/40 mg | 333 | Participants | ||
| Number of Participants That Experienced One or More Components of the Composite Clinical Endpoint of MCE (Major Cardiovascular Events) | Placebo | 355 | Participants | ||
| Number of Participants That Experienced One or More Components of the Composite Clinical Endpoint of AVE (Aortic Valve Events) | EZ/Simva 10/40 mg | 308 | Participants | ||
| Number of Participants That Experienced One or More Components of the Composite Clinical Endpoint of AVE (Aortic Valve Events) | Placebo | 326 | Participants | ||
| Number of Participants That Experienced One or More Components of the Composite Clinical Endpoint of ICE (Ischemic Cardiovascular Events) | EZ/Simva 10/40 mg | 148 | Participants | ||
| Number of Participants That Experienced One or More Components of the Composite Clinical Endpoint of ICE (Ischemic Cardiovascular Events) | Placebo | 187 | Participants | ||
| Cardiovascular Death | EZ/Simva 10/40 mg | 47 | Participants | ||
| Cardiovascular Death | Placebo | 56 | Participants | ||
| Aortic Valve Replacement (AVR) | EZ/Simva 10/40 mg | 267 | Participants | ||
| Aortic Valve Replacement (AVR) | Placebo | 278 | Participants | ||
| Congestive Heart Failure (CHF) Due to Progression of Aortic Stenosis (AS) | EZ/Simva 10/40 mg | 25 | Participants | ||
| Congestive Heart Failure (CHF) Due to Progression of Aortic Stenosis (AS) | Placebo | 23 | Participants | ||
| Nonfatal Myocardial Infarction (MI) | EZ/Simva 10/40 mg | 17 | Participants | ||
| Nonfatal Myocardial Infarction (MI) | Placebo | 26 | Participants | ||
| Coronary Artery Bypass Grafting (CABG) | EZ/Simva 10/40 mg | 69 | Participants | ||
| Coronary Artery Bypass Grafting (CABG) | Placebo | 100 | Participants | ||
| Percutaneous Coronary Intervention (PCI) | EZ/Simva 10/40 mg | 8 | Participants | ||
| Percutaneous Coronary Intervention (PCI) | Placebo | 17 | Participants | ||
| Hospitalization for Unstable Angina | EZ/Simva 10/40 mg | 5 | Participants | ||
| Hospitalization for Unstable Angina | Placebo | 8 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00092677/results